Federal: HR9559

Bill Summary

HR 9559, the IBOGAINE Act (Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act), accelerates development and patient access to psychedelic drugs for serious mental illness by establishing a National Health Priority Voucher Pilot Program for expedited drug review, expanding the federal right-to-try law to include Schedule I controlled substances, and revising DEA quota requirements to support faster production when drugs receive approval or breakthrough therapy designation. The bill also mandates timely rescheduling of compounds like ibogaine, promotes federal-state collaboration on psychedelic research and development, and creates a senior VA official position to oversee emerging therapeutic interventions with regular reporting requirements.

Why It Matters to MAHA

This bill directly aligns with MAHA's core commitment to health freedom and patient autonomy by removing regulatory barriers that prevent seriously ill patients from accessing potentially life-saving innovative treatments. By amending right-to-try provisions to include Schedule I substances and expediting the review process for psychedelic therapies, HR 9559 empowers patients to make their own medical choices rather than waiting years for traditional FDA approval timelines. The bill also supports transparency and evidence-based medicine by mandating rescheduling decisions and regular reporting on therapeutic outcomes. Critically, this legislation prioritizes veteran mental health and suicide prevention through dedicated VA oversight, addressing a healthcare crisis where conventional treatments have failed many patients. Expanding access to innovative neuroplastogenic compounds represents exactly the kind of treatment freedom and regulatory modernization MAHA advocates.